Open AccessRandomized Double-blind Comparison of Short-term Itraconazole and Terbinafine Therapy for Toenail Onychomycosis
Author(s) -
Hugo Degreef,
del Palacio A,
S. H. Mygind,
Gabriele Ginter,
Pinto Soares A,
Zuluaga de Cadena A
Publication year - 1999
Publication title -
acta dermato-venereologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.982
H-Index - 83
eISSN - 1651-2057
pISSN - 0001-5555
DOI - 10.1080/000155599750011020
Subject(s) - terbinafine , itraconazole , medicine , adverse effect , dermatology , randomized controlled trial , antifungal
Previous studies evaluating short-term itraconazole and terbinafine therapy for onychomycosis have varied in protocol and size; this double-blind study enabled a large-scale, standardized, direct comparison. Patients with toenail onychomycosis were randomized to itraconazole 200 mg daily (n = 146) or terbinafine 250 mg daily (n = 146) for 12 weeks, with a 36-week follow-up. Mycological cure rates at the follow-up end-point were significantly equivalent (61% with itraconazole vs. 67% with terbinafine). A similar proportion of patients in each group experienced adverse events during treatment (itraconazole, 22%; terbinafine, 23%). More patients receiving terbinafine stopped treatment permanently because of treatment-related adverse events (8% vs. 1%).